These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Immunomodulation for the prevention of SPIDDM and LADA. Pozzilli P; Guglielmi C Ann N Y Acad Sci; 2006 Oct; 1079():90-8. PubMed ID: 17130536 [TBL] [Abstract][Full Text] [Related]
26. Relation between cellular and humoral immunity to islet cell antigens in type 1 diabetes. Hummel M; Durinovic-Bello I; Ziegler AG J Autoimmun; 1996 Jun; 9(3):427-30. PubMed ID: 8816982 [TBL] [Abstract][Full Text] [Related]
27. Immune intervention in type I diabetes mellitus--current clinical and experimental approaches. Kolb H Exp Clin Endocrinol; 1994; 102(4):269-72. PubMed ID: 7813597 [TBL] [Abstract][Full Text] [Related]
28. Candidate genes and late-onset type 2 diabetes mellitus. Susceptibility genes or common polymorphisms? Hansen L Dan Med Bull; 2003 Nov; 50(4):320-46. PubMed ID: 14694850 [TBL] [Abstract][Full Text] [Related]
29. Genetics of Type 1 diabetes mellitus. Friday RP; Trucco M; Pietropaolo M Diabetes Nutr Metab; 1999 Feb; 12(1):3-26. PubMed ID: 10517302 [TBL] [Abstract][Full Text] [Related]
30. Immunopathogenesis and immunotherapy of type 1 diabetes. Wilson K; Eisenbarth GS Annu Rev Med; 1990; 41():497-508. PubMed ID: 2184747 [TBL] [Abstract][Full Text] [Related]
31. [Immunotherapy of insulin-dependent diabetes mellitus]. Satoh J; Seino H; Shintani S; Toyota T Nihon Rinsho; 1991 Feb; 49 Suppl():519-24. PubMed ID: 2033845 [No Abstract] [Full Text] [Related]
32. Hypothesis for the pathogenesis of type 1A diabetes. Jasinski JM; Eisenbarth GS Drugs Today (Barc); 2005 Feb; 41(2):141-9. PubMed ID: 15821785 [TBL] [Abstract][Full Text] [Related]
33. [Immunointervention in type 1 diabetes mellitus]. Vialettes B Diabete Metab; 1992; 18(1):3-10; discussion 11-3. PubMed ID: 1563533 [No Abstract] [Full Text] [Related]
34. Immunosuppressive therapy in newly diagnosed diabetic children (comparison between two different strategies). Pocecco M; Marinoni S; Tonini G; Tedesco F J Endocrinol Invest; 1989; 12(8 Suppl 3):143-4. PubMed ID: 2809092 [No Abstract] [Full Text] [Related]
35. Pathophysiology of immune-mediated (type 1) diabetes mellitus: potential for immunotherapy. Abel M; Krokowski M BioDrugs; 2001; 15(5):291-301. PubMed ID: 11437693 [TBL] [Abstract][Full Text] [Related]
36. New developments in non-specific and semi-specific immunosuppression in type I diabetes. Leslie RD; Carotenuto P; Pozzilli P Diabetes Metab Rev; 1993 Dec; 9(4):257-67. PubMed ID: 7924823 [No Abstract] [Full Text] [Related]
37. Immunotherapies currently in development for the treatment of type 1 diabetes. Davis IC; Randell J; Davis SN Expert Opin Investig Drugs; 2015; 24(10):1331-41. PubMed ID: 26364507 [TBL] [Abstract][Full Text] [Related]
38. [Has immunotherapy a place in insulin-dependent diabetes of children?]. Lestradet H Bull Acad Natl Med; 1988 Feb; 172(2):143-9. PubMed ID: 3042098 [No Abstract] [Full Text] [Related]
40. [Perspectives of immunosuppressive treatment for the prevention of diabetes mellitus type I]. Estopiñán García V; Fortea Gimeno L An Med Interna; 1992 Oct; 9(10):471-2. PubMed ID: 1420756 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]